Welcome to the EPA 2022 Interactive Programme
The congress will officially run on Central European Summer Time (CEST/GMT +2)
To convert the congress times to your local time Click Here
Fully Live with Live Q&A 
On Demand (available from 4 June) 
ECP Session 
Section Session 
EPA Course (Pre-Registration Required)
Ask the Expert 
Sessions with Voting 
Live TV 
Product Theatre
Session Description:
The first lecture will set the stage and give an overview on complex cases in schizophrenia - like patients presenting with depressive, negative and cognitive symptoms, hostility, or comorbid substance use - and the clinical challenges in their treatment. Then, the findings of a network analysis will be presented, investigating how depressive symptoms relate to other PANSS symptom dimensions in patients with schizophrenia who have predominant negative symptoms. Next, the second lecture will discuss how partial agonists can improve such complex cases by addressing a wide range of symptoms. Finally, the third lecture will focus on cariprazine’s advantages in the treatment of complex cases, and illustrate it via a case report.
Introduction
Depressive symptoms and PANSS symptom dimensions in patients with predominant negative symptom schizophrenia: a network analysis
Molecular Imaging of Dopamine Partial Agonists in Humans: Implications for Clinical Practice
Cariprazine, schizophrenia and substance abuse: the opportunity for a new approach